- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Alamar Biosciences, Inc.: Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology | 1 | GlobeNewswire (USA) | ||
| 05.10. | Alamar Biosciences, Inc.: Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team | 290 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR) a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced... ► Artikel lesen | |
| 25.09. | Alamar Biosciences, Inc.: Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment | 1 | GlobeNewswire (USA) | ||
| 24.09. | Alamar Biosciences stock rating reiterated at Buy by TD Cowen | 1 | Investing.com | ||
| 21.09. | Alamar Biosciences: Starke Quartalszahlen und erhöhte Prognose beflügeln die Aktie | 3 | Investing.com Deutsch | ||
| ALAMAR BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 12.08. | Biotech Stocks At 52-Week Highs - Alamar Biosciences +30% on Q2 Reports, Dyne Therapeutics, Cullinan Therapeutics, DexCom, Cardinal Health | 2.803 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.Alamar Biosciences Inc.... ► Artikel lesen | |
| 11.08. | Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum | 2 | Benzinga.com | ||
| 11.08. | Stifel raises Alamar Biosciences stock price target on earnings beat | 1 | Investing.com | ||
| 11.08. | Alamar outlines $116M-$120M 2026 revenue outlook while targeting 100+ instruments and $400,000+ pull-through | 1 | Seeking Alpha | ||
| 10.08. | Alamar Q2 2026 slides: consumables surge 147%, margin hits 60% | 1 | Investing.com | ||
| 10.08. | Alamar Biosciences: Starkes Umsatzwachstum und Rekordmarge bei anhaltenden Verlusten | 4 | Investing.com Deutsch | ||
| 10.08. | Alamar Biosciences expands proteomics partnership by 86,000 samples | 3 | Investing.com | ||
| 10.08. | Alamar Biosciences erweitert Proteomik-Partnerschaft um 86.000 Proben | - | Investing.com Deutsch | ||
| 10.08. | Alamar Biosciences, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 10.08. | Alamar Biosciences, Inc.: Alamar Biosciences Expands Global Partnership with Alzheimer's Disease Data Initiative and Gates Ventures | 3 | GlobeNewswire (USA) | ||
| 28.07. | Alamar Biosciences launches immune profiling panel for research | 1 | Investing.com | ||
| 28.07. | Alamar Biosciences stellt neues Panel zur Immunprofilierung für die Forschung vor | 2 | Investing.com Deutsch | ||
| 28.07. | Alamar Biosciences, Inc.: Alamar Biosciences Launches NULISAseq Immune 340 Panel for Comprehensive Profiling of the Immune Proteome | 516 | GlobeNewswire (Europe) | Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging
Highly sensitive... ► Artikel lesen | |
| 27.07. | Cathie Woods Biotech-Offensive lenkt den Blick auf datengetriebene Healthcare-Unternehmen - Emyria baut klinische Präsenz aus | Small- & Micro Cap Investment | |||
| 15.07. | Alamar Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,090 | +0,09 % | Neue Aufträge, neuer Aktionär, neues Gebot: Frische Fantasie bei HPQ Silicon, CTS Eventim und Qiagen | Erstellt und veröffentlicht im Auftrag von HPQ Silicon Manchmal genügt eine einzige Nachricht, um die Geschichte hinter einer Aktie neu zu schreiben. Bei HPQ Silicon sollen zertifizierte Hochleistungszellen... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 44,250 | -1,84 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Enliven continues preparation for late-stage... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 18,155 | 0,00 % | Mineralys Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 126,72 | +3,40 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| TANGO THERAPEUTICS | 22,710 | +0,89 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| BAMBUSA THERAPEUTICS | 14,900 | 0,00 % | Bambusa Therapeutics, Inc.: Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering | BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or " Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-acting... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,025 | -7,47 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| COGENT BIOSCIENCES | 31,000 | -3,06 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| SUMMIT THERAPEUTICS | 16,030 | -1,05 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| VOR BIOPHARMA | 19,680 | -5,88 % | Vor Bio Down on Q3 Results | ||
| KINIKSA PHARMACEUTICALS | 92,10 | -5,60 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| PRIME MEDICINE | 4,720 | -9,92 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen | |
| ERASCA | 14,330 | -4,34 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| ABSCI | 11,125 | -8,06 % | Jefferies nimmt Absci mit "Buy" auf - Potenzial bei Wirkstoff gegen Haarausfall im Fokus | ||
| NURIX THERAPEUTICS | 26,780 | -1,25 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen |
ALAMAR BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 30,610 Euro und damit -9,97 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALAMAR BIOSCIENCES INC finden Sie auf Wallstreet Online.